Pyr, JELIS (no mineral oil used) showed a 19% RRR with 1.8g EPA/day. REDUCE-IT, which showed a 25% RRR with 4g EPA/day, could be viewed as a confirmatory trial with p<.00000001. In fact, the 25% RRR is actually an understatement of the true RRR of 4g/day EPA therapy due to patient compliance issue especially in Eastern Europe/Russia. To conclude, the REDUCE-IT trial result is iron clad.
4g/day EPA cuts CV death by 20%. Your hypothesis, 4g/day mineral oil causing malabsorption of lipid medications hence producing additional 20% in CV death despite none of those available lipid medications have any proven CV death reduction benefits, does not make theoretical and practical sense.
News 
Market Data 
Discover 
